Genscript Biotech Corporation
GNNSF | OTC
$4.50
$0.00 (0.00%)
Nov 2, 2026, 9:52 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -6.38 | -40.85 | 12.17 | -28.92 | -24.58 | -13.18 |
PEG Ratio | -0.01 | 0.35 | -0.04 | 0.74 | -0.39 | -0.12 |
PS Ratio | 3.60 | 4.64 | 9.16 | 10.66 | 18.32 | 7.05 |
PB Ratio | 0.87 | 0.64 | 3.69 | 6.60 | 8.59 | 3.06 |
P/FCF Ratio | 14.31 | -38.16 | -11.55 | -19.83 | -33.28 | -10.09 |
P/OCF Ratio | 10.62 | 36.46 | -17.90 | -55.44 | -65.65 | -18.23 |
OCF/S Ratio | 33.93 | 12.72 | -51.19 | -19.23 | -27.91 | -38.66 |
Debt / Equity Ratio | 0.07 | 0.17 | 0.30 | 0.35 | 0.15 | 0.06 |
Quick Ratio | 1.41 | 2.62 | 4.65 | 3.12 | 3.86 | 2.93 |
Current Ratio | 1.47 | 2.72 | 4.76 | 3.23 | 3.97 | 3.03 |
Asset Turnover | 0.20 | 0.11 | 0.17 | 0.25 | 0.22 | 0.27 |
Interest Coverage | 14.74 | 1.16 | 0.95 | -33.02 | -159.50 | n/a |
Return on Equity | -13.46% | 68.54% | -6.86% | -22.45% | -34.29% | -22.73% |
Return on Assets | -10.98% | 56.11% | -2.82% | -8.91% | -16.06% | -14.16% |
Return on Invested Capital | 5.54% | 0.18% | 0.85% | -22.50% | -21.31% | -17.82% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 57.65% | 45.77% | 48.29% | 48.60% | 57.65% | 65.47% |
Net Profit Margin | -55.53% | 498.22% | -17.03% | -36.26% | -73.19% | -52.44% |
Pretax Profit Margin | -49.04% | -28.73% | 30.13% | -68.99% | -105.56% | -72.13% |
Operating Profit Margin | 26.60% | 1.56% | 4.67% | -70.02% | -77.39% | -52.33% |
FCF Margin | 25.19% | -12.16% | -79.33% | -53.76% | -55.06% | -69.84% |
EBITDA Margin | 33.10% | 11.78% | 14.90% | -62.18% | -97.38% | -44.70% |
Add to Watchlist
Select watchlists to add or remove GNNSF